28 August 2025
ECO Animal Health Group plc
("ECO" or the "Company")
Posting of Annual Report and Notice of AGM
ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announces that its Annual Report and Accounts for the year ended 31 March 2025 ("Annual Report"), Notice of Annual General Meeting ("AGM") and Form of Proxy have today been posted to shareholders who have elected to receive hard copies by post.
The Company will hold its AGM at The Grange, 100 High Street, London, N14 6BN on Thursday 25 September 2025 at 09.00am.
The Annual Report, Notice of AGM and Form of Proxy will be made available on the Company's website at https://ecoanimalhealth.com/investors/.
-Ends-
Contacts
|
ECO Animal Health Group plc David Hallas (Chief Executive Officer) Christopher Wilks (Chief Financial Officer)
|
|
|
ICR Healthcare (Financial PR) Mary-Jane Elliott Jessica Hodgson
|
020 3709 5700
|
|
Singer Capital Markets (Nominated Adviser & Joint Broker) Philip Davies Sam Butcher
|
020 7496 3000 |
|
Investec (Joint Broker) Gary Clarence Lydia Zychowska
|
020 7597 5970
|
|
Equity Development Hannah Crowe Matt Evans |
020 7065 2692 |
|
|
|
About ECO Animal Health
ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.
Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.
Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.
Click here for more information: https://ecoanimalhealth.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
